Intec Pharma Ltd (NASDAQ:NTEC) Short Interest Up 191.6% in December


Share on StockTwits

Intec Pharma Ltd (NASDAQ:NTEC) saw a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 330,400 shares, an increase of 191.6% from the December 15th total of 113,300 shares. Currently, 9.2% of the shares of the company are short sold. Based on an average daily trading volume, of 759,200 shares, the days-to-cover ratio is currently 0.4 days.

NTEC has been the subject of a number of research reports. LADENBURG THALM/SH SH upgraded Intec Pharma from a “neutral” rating to a “buy” rating and set a $13.00 price objective for the company in a research note on Wednesday, December 9th. ValuEngine cut Intec Pharma from a “buy” rating to a “hold” rating in a research note on Thursday, October 1st. Zacks Investment Research upgraded Intec Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, October 13th. HC Wainwright restated a “hold” rating on shares of Intec Pharma in a research note on Friday, October 9th. Finally, Roth Capital restated a “neutral” rating on shares of Intec Pharma in a research note on Tuesday, December 15th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Intec Pharma has an average rating of “Hold” and an average price target of $9.00.

NASDAQ NTEC opened at $4.25 on Thursday. The company has a 50-day simple moving average of $3.78 and a two-hundred day simple moving average of $5.10. Intec Pharma has a 12-month low of $2.20 and a 12-month high of $15.82. The firm has a market cap of $15.27 million and a price-to-earnings ratio of -0.59.

Intec Pharma (NASDAQ:NTEC) last posted its earnings results on Thursday, November 5th. The biotechnology company reported ($0.95) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.80) by ($0.15). Equities analysts expect that Intec Pharma will post -4.21 earnings per share for the current year.

Hedge funds have recently modified their holdings of the stock. AdvisorShares Investments LLC increased its position in Intec Pharma by 17.9% during the third quarter. AdvisorShares Investments LLC now owns 533,255 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 80,967 shares during the last quarter. GSA Capital Partners LLP purchased a new position in Intec Pharma in the third quarter worth approximately $55,000. Russell Investments Group Ltd. purchased a new position in Intec Pharma in the second quarter worth approximately $29,000. Finally, Two Sigma Advisers LP lifted its stake in Intec Pharma by 326.1% in the second quarter. Two Sigma Advisers LP now owns 88,200 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 67,500 shares during the last quarter.

Intec Pharma Company Profile

Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.

Read More: What is the strike price in options trading?

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.